Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 10/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526940 | 0.92 | HPGD (0.56) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3521534 | 0.91 | MAPK14 (0.67) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3519707 | 0.89 | MAPK14 (0.59) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3521113 | 0.89 | MAPK14 (0.58) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3518463 | 0.88 | KDM4E (0.51) | MAPK14KDM4EHPGDMAPTALDH1A1 | |
| SCHEMBL3518434 | 0.87 | MAPK14 (0.55) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3519640 | 0.86 | MAPK14 (0.56) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3520149 | 0.85 | MAPK14 (0.55) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3520704 | 0.85 | MAPK14 (0.53) | MAPK14KDM4EHPGDNPSR1MAPT | |
| SCHEMBL3520146 | 0.85 | MAPK14 (0.55) | MAPK14KDM4EHPGDNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885KDM4E 3806/4885HPGD 418/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885KDM4E 3935/4885HPGD 442/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885KDM4E 3806/4885HPGD 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.